The therascreen® PIK3CA RGQ PCR Kit diagnostic test, (QIAGEN Manchester, Ltd.), has also been approved to detect patients with PIK3CA mutations, which can be performed either on tumour tissue samples and/or in circulating tumour DNA (ctDNA) in plasma [195]. Here, PIK3CA is linked to neoplasm.